<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4298">
  <stage>Registered</stage>
  <submitdate>12/02/2014</submitdate>
  <approvaldate>12/02/2014</approvaldate>
  <nctid>NCT02063295</nctid>
  <trial_identification>
    <studytitle>An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury</studytitle>
    <scientifictitle>Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZAF-221</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Over-weight</healthcondition>
    <healthcondition>Hypothalamic Injury</healthcondition>
    <healthcondition>Craniopharyngioma</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZGN-440 sterile diluent
Treatment: drugs - ZGN-440 for injectable suspension

Placebo Comparator: ZGN-440 sterile diluent - Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.

Experimental: ZGN-440 for injectable suspension - Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.


Treatment: drugs: ZGN-440 sterile diluent
ZGN-440 sterile diluent/placebo

Treatment: drugs: ZGN-440 for injectable suspension


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in body weight from baseline to the end of the randomized dosing period.</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in lipid profile (cholesterol, LDL, HDL, triglycerides) from baseline to the end of the randomized dosing period</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in hs-CRP from baseline to the end of the randomized dosing period.</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in hunger from baseline to the end of the randomized dosing period.</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in quality of life from baseline to the end of the randomized dosing period.</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by
             BMI =30 and =60 kg/m2

          -  Greater than 6 months post-treatment, including chemotherapy, surgery or radiation
             with resulting injury to the hypothalamus and/or the pituitary

          -  Stable body weight for at least 3 months

          -  Type 2 diabetes mellitus is allowed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Males taking gonadotropin replacement therapy (LH/FSH)

          -  Subjects who are planning any fertility treatment within 6 months of study
             participation

          -  Use of weight loss agents, including herbal medications, in the past 3 months

          -  Current or anticipated chronic use of narcotics or opiates

          -  History of severe psychiatric disorders

          -  Type 1 diabetes mellitus

          -  Metabolic disorders or genetic disorders linked to obesity

          -  History of any bariatric surgery

          -  Participation in any clinical study with an investigational drug or device within the
             3 months prior to enrollment in this study

          -  Blood loss or donation &gt;500 mL within the past 3 months

          -  Females who are pregnant, nursing, intend to become pregnant during the study or any
             males who plan to father/conceive a child within 6 months after completion of study
             participation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>14</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>The Boden Institute - Sydney</hospital>
    <hospital>Austin Health, Metabolic Disorders Centre - Heidelberg Heights</hospital>
    <postcode>2006 - Sydney</postcode>
    <postcode>3081 - Heidelberg Heights</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zafgen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
      beloranib in obese subjects with hypothalamic injury.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02063295</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>